InfuSystem Holdings, Inc. (NYSE:INFU) Shares Sold by ARS Investment Partners LLC

ARS Investment Partners LLC reduced its holdings in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 7.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,787 shares of the company’s stock after selling 1,853 shares during the period. ARS Investment Partners LLC owned approximately 0.10% of InfuSystem worth $184,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of InfuSystem by 74.1% during the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock valued at $104,000 after buying an additional 6,623 shares during the last quarter. Barclays PLC increased its holdings in shares of InfuSystem by 300.5% in the third quarter. Barclays PLC now owns 28,597 shares of the company’s stock valued at $192,000 after purchasing an additional 21,457 shares during the period. Geode Capital Management LLC increased its holdings in shares of InfuSystem by 1.8% in the third quarter. Geode Capital Management LLC now owns 436,508 shares of the company’s stock valued at $2,925,000 after purchasing an additional 7,550 shares during the period. State Street Corp raised its stake in shares of InfuSystem by 1.1% in the third quarter. State Street Corp now owns 267,012 shares of the company’s stock worth $1,789,000 after purchasing an additional 3,019 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of InfuSystem by 66.4% during the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after purchasing an additional 1,626 shares during the period. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

InfuSystem Trading Up 3.1 %

Shares of INFU stock opened at $8.23 on Wednesday. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 12-month low of $5.74 and a 12-month high of $10.03. The business’s 50 day simple moving average is $8.54. The stock has a market capitalization of $175.00 million, a P/E ratio of 137.19 and a beta of 1.53.

InfuSystem (NYSE:INFU) last announced its earnings results on Thursday, November 7th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. The firm had revenue of $35.32 million for the quarter, compared to analyst estimates of $35.50 million. InfuSystem had a return on equity of 2.78% and a net margin of 1.12%. On average, research analysts predict that InfuSystem Holdings, Inc. will post 0.15 earnings per share for the current fiscal year.

Insider Transactions at InfuSystem

In other InfuSystem news, CEO Richard Dilorio sold 5,398 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $8.87, for a total transaction of $47,880.26. Following the completion of the sale, the chief executive officer now directly owns 416,659 shares in the company, valued at approximately $3,695,765.33. The trade was a 1.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.20% of the company’s stock.

Analyst Upgrades and Downgrades

INFU has been the topic of several recent research reports. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th. B. Riley began coverage on InfuSystem in a research report on Thursday, September 26th. They set a “buy” rating and a $13.00 price target on the stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.